CAS: 111047-30-4; Ginkgolic Acid C17:1

上下游产品

6-<(Z)-10-Heptadecenyl>-2-Methoxybenzoic Acid 173473-56-8
6-(9-Bromononyl)-2-Methoxybenzoic Acid 173473-50-2
6-(9-Hydroxynonyl)-2-Methoxybenzoic Acid 173473-49-9
6-(10-Heptadecynyl)-2-Methoxybenzoic Acid 173473-54-6
6-甲基水杨酸乙酯/2-羟基-6-甲基苯甲酸乙酯 Ethyl 2-Hydroxy-6-Methylbenzoate 6555-40-4

Methyl 12-(Tetrahydro-2H-Pyran-2-Yloxy)-2-Dodecynoate置于lindlar'S Catalyst 吡啶,喹啉,氢氧化钾,Aluminium(III) Iodide,正丁基锂,2,3-二氯马来酸酐,四溴化碳,氢气,对甲苯磺酸,三苯基膦,环己烯体系中,用 四氢呋喃,甲醇,二硫化碳,六甲基磷酰三胺,乙醇,正己烷,二氯甲烷,环己烷 用作溶剂,25.0~200.0 °C,100.0 Kpa 条件下,反应 4.5H,反应生成银杏酸 C17:1
参考文献:Zehnter,Reinhard; Gerlach,Hans,Liebigs Annalen,1995,# 12,P. 2209-2220
标题:Zehnter,Reinhard; Gerlach,Hans,Liebigs Annalen,1995,# 12,P. 2209-2220

专利信息

专利号:US-2024336679-A1
优先权日:2021-08-06
标题 :Methods for the treatment of cancer
发明人：LINARES LÆTITIA; FIRMIN NELLY; MANTEAUX GABRIELLE
权利人:INST REGIONAL CANCER MONTPELLIER; INST NAT SANTE RECH MED; UNIV MONTPELLIER
摘要:The present disclosure relates to an Interleukin-6 (IL-6) signaling inhibitor selected from an IL-6 inhibitor, an IL-6 receptor inhibitor, an IL-6/IL-6 receptor complex inhibitor, a gp130 inhibitor and a STAT3 inhibitor or a pharmaceutical composition comprising such an IL-6 signaling inhibitor. for use in a method for treating and/or preventing cancer in a subject in need thereof. wherein the subject has been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin. The inventors have observed that cancers exhibiting recruitment of MDM2 to chromatin have been shown to secrete IL-6 that in turn acts on myoblast cells to activate serine synthesis. Following these surprising and unexpected observations. the inventors set up methods of treatment that are able to induce cancer cells death in subjects that have been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin.